BioTime, Inc. (BTX) Given Consensus Recommendation of “Buy” by Brokerages
Shares of BioTime, Inc. (NYSEAMERICAN:BTX) have been assigned an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.50.
A number of equities analysts have recently weighed in on BTX shares. Oppenheimer started coverage on shares of BioTime in a research note on Tuesday, December 11th. They set an “outperform” rating and a $3.50 price target on the stock. CIBC started coverage on shares of BioTime in a research note on Tuesday, December 11th. They set an “outperform” rating and a $3.50 price target on the stock. Zacks Investment Research raised shares of BioTime from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Thursday, January 3rd. Maxim Group initiated coverage on shares of BioTime in a research note on Thursday, January 24th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Dawson James initiated coverage on shares of BioTime in a research note on Thursday, February 7th. They issued a “buy” rating on the stock.
NYSEAMERICAN:BTX opened at $1.55 on Friday. BioTime has a fifty-two week low of $0.66 and a fifty-two week high of $2.81.
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.